Journal of Dermatitis

Abstract

Safety and Effectiveness of Inactivated Streptococcus thermophilus Atcc 19258 (Neoimmuno Hilus Gb®) Lotion on Atopic Dermatitis: A Randomized Placebo-Controlled Clinical Trial

Marina Piola Rossetto, Gabriel Fernandes Alves Jesus, Ana Paula Voytena, Silvia Dal-Bó, Zoé Feuser, Heloisa de Medeiros Borges and Monique Michels*

Aim: Our aim was evaluated the safety and clinical efficacy of a posbiotic lotion in the treatment of atopic dermatitis.

Methods: Randomized, double-blind, placebo-controlled clinical trial was performed in patients who had any degree of atopic dermatitis. A total of 24 volunteers were recruited and randomly divided into two groups: Placebo or Treated. (1% NEOIMUNO HILUS GB®). The ingredient used was NEOIMUNO HILUS GB® (Streptococcus thermophilus strain ATCC 19258). Physical analysis to determine the dermatitis degree and perception questionnaire was applied before and after treatment. The questionnaire included questions about perception of itching, oiliness, humidity and product quality. Statistical analyses were performed.

Results: The volunteers in the Treated Group showed a significant improvement in skin balance, moisture and oiliness after 28 days of using the NEOIMUNO HILUS GB® posbiotic lotion. The perception of the variable “skin irritation”, “flaking” and “itching” by the Treated Group showed a significant increase in the number of people who showed improvement in their condition (“Improved”).

Conclusion: Finally, the posbiotic lotion 1% (NEOIMUNO HILUS GB®) showed safety and efficacy in the treatment of the skin of people with atopic dermatitis.

Published Date: 2023-07-17; Received Date: 2023-06-14